Cancer Treatment Using Inhibitors of Tyrosyl-Dna Phosphodiesterase (Tdp1)
Background:
The National Cancer Institute's
Laboratory of Molecular Pharmacology is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize inhibitors
of Tyrosyl-DNA phosphodiesterase (Tdp1). The technology is also
available for exclusive and non-exclusive
licensing.
Technology:
Tyrosyl-DNA phosphodiesterase
(Tdp1) is an enzyme that repairs topoisomerase I (Top1)-mediated
DNA damage induced by chemotherapeutic agents and ubiquitous DNA
lesions that interfere with transcription. The current technology
involves steroid derivatives that inhibit Tdp1.
Currently, there are various types of Top1 inhibitors used in
chemotherapy. However, Tdp1 inhibitors are expected to be effective
in combination therapy with Top1 inhibitors for the treatment of
cancers.
R&D Status:
Pre-clinical (discovery)
IP Status:
U.S. Provisional Application No. 60/921,980 filed 05 Apr 2007
Value Proposition:
- Combining Tdp1 inhibitors with Top1 inhibitors would allow Tdp1
to potentiate the anti-proliferative activity of Top1
inhibitors
- May have selective activity towards tumor tissues
- Tdp1 inhibitors can also exhibit antitumor activity
independently, as tumors are shown to have excess free radicals,
and Tdp1 repairs DNA damage by oxygen radicals.
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #588 LF
Posted on 12/06/2007